Last updated: February 15, 2026
Overview
NDC 60842-0023 is a formulation of adalimumab, branded as Humira and its biosimilar counterparts. The drug is widely used for autoimmune conditions, including rheumatoid arthritis, Crohn’s disease, psoriasis, and ankylosing spondylitis. Its market landscape is characterized by high demand, patent expirations, biosimilar entry, and evolving pricing strategies.
Market Size and Trends
The global market for adalimumab reached approximately USD 17.3 billion in 2022, according to IQVIA. North America accounts for 55-60% of this volume, driven by high prevalence of autoimmune disorders and established healthcare infrastructure. The market is expected to grow at a CAGR of 6-8% over the next five years, reaching over USD 25 billion by 2028[1].
Key factors influencing growth:
- Patent expirations: The original Humira patent expired in the US in January 2023, opening the market for biosimilars.
- Biosimilar entry: Multiple biosimilars launched in 2023-2024, introducing price competition.
- R&D pipeline: Ongoing development of novel biologics and biosimilars targeting similar indications.
Pricing Landscape
Original Humira (AbbVie):
- Average Wholesale Price (AWP): approx. USD 5,000–6,000 per treatment dose.
- Annual treatment cost: USD 70,000–USD 80,000, varying by indication and dosing.
Biosimilars (post-2023):
- Entry prices are approximately 15-20% lower than the originator.
- Typical price range: USD 4,000–USD 5,000 per treatment dose.
- Price reductions will likely escalate with increased biosimilar competition, potentially reaching 30%–40% below the originator by 2025[2].
Market Entry Barriers and Competitive Dynamics
- Regulatory requirements: Approval necessitates robust biosimilarity data, though these are less complex than for novel biologics.
- Manufacturing complexity: Biosimilars require advanced biomanufacturing and quality controls.
- Brand loyalty: Prescribers and patients familiar with Humira may delay switching, affecting early biosimilar penetration.
- Pricing strategies: Originator companies may implement rebate programs or tiered pricing to maintain market share.
Pricing Projections (2023–2028)
| Year |
Estimated Average Price (USD) per Dose |
Market Penetration of Biosimilars |
Total Market Size (USD Billions) |
| 2023 |
5,500 |
5% |
17.5 |
| 2024 |
5,250 |
15% |
20.0 |
| 2025 |
4,800 |
35% |
22.5 |
| 2026 |
4,500 |
50% |
24.0 |
| 2027 |
4,300 |
65% |
25.0 |
| 2028 |
4,000 |
75% |
25.5 |
This model assumes a steady increase in biosimilar adoption, reducing average prices and sustaining overall market growth due to rising demand.
Implications for Stakeholders
- Biotech companies: Entry of biosimilars drives downward pressure on prices, reducing profit margins for originators.
- Payers and insurers: Cost containment strategies will focus on encouraging biosimilar substitution; expected annual savings could reach USD 10–20 billion by 2028.
- Patients: Access should improve due to lower prices; however, prescriber acceptance influences biosimilar uptake rates.
Risks and Uncertainties
- Delays in biosimilar approval or market entry.
- Regulatory reforms affecting biosimilar substitution policies.
- Patent disputes, such as secondary patents, potentially delaying biosimilar launch.
- New biologics entering the market with alternative mechanisms of action.
Key Takeaways
- The market for NDC 60842-0023 will experience significant price reductions driven by biosimilar competition, with prices declining by up to 30-40% over five years.
- The overall market size is projected to grow to approximately USD 25.5 billion by 2028, supported by increasing adoption and expanding indications.
- Payers and providers will prioritize biosimilar use to manage costs, influencing pricing strategies and market shares.
- Patent litigation and regulatory policies will shape the timing and extent of biosimilar market penetration.
- The landscape presents both risks and opportunities for stakeholders in biologic drug development and distribution.
FAQs
1. How do biosimilars impact the market price for adalimumab?
Biosimilars introduce price competition that reduces average treatment costs. Prices can decrease by 15-20% shortly after entry and up to 30-40% within a few years, depending on market uptake and manufacturer strategies.
2. What are the main barriers to biosimilar adoption?
Physician and patient familiarity with originator brand, regulatory policies on interchangeability, manufacturing complexities, and rebate or contract strategies by originator companies.
3. How do patent expirations influence market entry?
Patent expirations remove legal barriers, allowing biosimilar manufacturers to seek approval and commercialization. Legal disputes over secondary patents can delay entry.
4. What are the anticipated trends in prices from 2023 to 2028?
Prices are expected to decrease by approximately 10-15% annually, driven by biosimilar proliferation and increasing market competition.
5. How will the overall market size change?
Despite lower prices, the total market size is projected to grow as demand increases due to expanded indications and greater accessibility.
Citations
[1] IQVIA. "Global Biologics Market Report 2022."
[2] EvaluatePharma. "Biosimilar Market Trends and Pricing Data," 2023.
